Systemic Sclerosis Insights (9.13.2024)
Dr. Jack Cush reviews the news and journal articles from this past week on RheumNow.com.
Read Article
VASCULTIS Literature analysis shows most frequent citations, research centers and reveals the top 3 vasculitis topics to be:
1. Immune checkpoint inhibitors
2. GPA/Wegener's granulomatosis
3. SLE - lupus vasculopathy
https://t.co/FS2cuv9gt4 https://t.co/ziI4sfexrm
Dr. John Cush @RheumNow( View Tweet )
CORRECTION!! UCB announced the LAUNCH of a new phase 3b BE BOLD trial - this study has no report results as yet. It WILL BE a H2H RCTcomparing bimekizumab & rizankizumab in adult #PsA pts using an ACR50 primary endpoint. Yesterday we incorrectly reported this as a completed… https://t.co/apa6VMuQTi https://t.co/BTpwo6ww7W
Dr. John Cush @RheumNow( View Tweet )
RheumNow Live 2025: Redefining Rheumatology Practice, Transform your practice. Elevate your expertise. RheumNow Live 2025 – Where Rheumatology Thrives!
Reserve Your Spot: https://t.co/o78Pc8LPsQ https://t.co/Gb9ZAg2GLt
Links:
Dr. John Cush @RheumNow( View Tweet )
ACR 2024 Abstracts are available.
Let the fun begin.....
https://t.co/uNLZBqjEX0
Search by term, title or abstract # here: https://t.co/Du1eN4gA9D
or
Search by sessions and topics here >> https://t.co/R7NH1jeHPj https://t.co/OCoTPr03nG
Links:
Dr. John Cush @RheumNow( View Tweet )
Systemic Sclerosis Insights (9.13.2024)
https://t.co/fRbKdSAqxG https://t.co/PMbYDXPHMd
Dr. John Cush @RheumNow( View Tweet )
Linger on the Fingers (9.6.2024)
Dr. Jack Cush reviews the news and journal reports from the past week on RheumNow. This week with a focus on fingers and better prescriptive follow through.
https://t.co/c9yvRjE9av https://t.co/mdN37AWHjX
Dr. John Cush @RheumNow( View Tweet )
Claims analysis of two datasets showed TNFi treatment in 1st two years after newly Dx breast cancer (n 2216) had no effect on overall survival (OS); but had signif better breast cancer survival (HR 0.28; 0.08–0.98) vs csDMARD Rx. Pts on GC worse OS (HR 2.18)… https://t.co/Kxk7Sy7ahi https://t.co/PtxRsTifi1
Dr. John Cush @RheumNow( View Tweet )
Does Rheumatoid Factor Influence Anti-TNF Responses in RA?
Smolen and colleagues have published a subanalysis of the EXXELERATE study that showed while certolizumab pegol [CZP] concentrations and efficacy was unaffected by high titers of rheumatoid factor (RF), patients treated… https://t.co/Ux9gHXcGbv https://t.co/gpcuWrqVHi
Dr. John Cush @RheumNow( View Tweet )
Does Rheumatoid Factor Influence Anti-TNF Responses in RA?
Smolen and colleagues have published a subanalysis of the EXXELERATE study that showed while certolizumab pegol [CZP] concentrations and efficacy was unaffected by high titers of rheumatoid factor (RF), patients treated with adalimumab had a blunted response in the face of high RF titers.
Read Article
Claims analysis, shows <0.5% of IBD or RA pts developed an invasive fungal infx within 1 year of TNF therapy initiation (. Histoplasmosis was the most common
IBD = 3.3 IFI/100PY
RA = 2.8 IFF/100PY https://t.co/ER9YCxecJT https://t.co/T0UNgB4h6R
Dr. John Cush @RheumNow( View Tweet )
Immunomodulatory Prevention of Uveitis Relapse in Behçet's
The results of a randomised, open-label, head-to-head trial shows that adalimumab was superior to ciclosporin in preventing uveitis relapses in patients with severe Behçet's disease.
Read Article
Study of 425 RA pts & 36 mo. bDMARD retention rates w/ TNFi, IL-6i & ABA based on renal funct (eGFR: ≥60, 30–60, <30 mL/min) showing little effect of CKD w/ TNFi (45%, 28%, 34%), IL-6i (47%, 67%, 71%) & CTLA-4Ig (50%, 31%, 33%), maybe lower w/ TNFi & higher w/ IL6i… https://t.co/FhXoSnEfG1 https://t.co/N29nLBOoUj
Dr. John Cush @RheumNow( View Tweet )
ACR Applauds Lower Negotiated Prices for Common Arthritis Drugs
The ACR praised the recent announcement from the CMS that their initial drug pricing negotiations have reduced costs for select medications, including significantly lower prices for Enbrel and Stelara, which are… https://t.co/GXl6y87ZaF https://t.co/A2N4Ehg8Dk
Dr. John Cush @RheumNow( View Tweet )
Sequential Belimumab and Rituximab in SLE
Could disease control in active systemic lupus erythematosus (SLE) patients be improved by the sequential use of subcutaneous belimumab (BEL) and intravenous rituximab (RTX)? A double blind trial has shown that sequential BEL and RTX was not superior to BEL alone in SLE.
Read Article
ACR Applauds Lower Negotiated Prices for Common Arthritis Drugs
The American College of Rheumatology praised the recent announcement from the Centers for Medicare & Medicaid Services (CMS) that their initial drug pricing negotiations have reduced costs for select medications, including significantly lower prices for Enbrel and Stelara, which are
Read Article
Higher Cancer Rates (8.16.2024)
Dr. Jack Cush reviews the news and journal reports from the past week on RheumNow.com, noting his concerns about diet, cancer, ILD, death and dosing challenges.
Read Article
Rheums! Have a Rheumatology question or case for Jack Cush? Record it here and we'll feature it on an upcoming podcast. Tell us your name and where you practice rheumatology.
https://t.co/GV6WjsqZBH https://t.co/9l9qyJpg3I
Dr. John Cush @RheumNow( View Tweet )
Breast CA (BC) & TNFi - study of 2 cohorts (Optum commercial * SEER/Medicare) found that 17% & 16% of BC pts received TNFi. 1 yr overall survival was no different +/- TNFi (HR= 0.77 & 0.84); but BC survival better on TNFi (HR 0.28; 0.08–0.98) vs csDMARDs. https://t.co/cGqT80rGTR https://t.co/n7i5VNFkVT
Dr. John Cush @RheumNow( View Tweet )
Systematic review: RX of macrophage activation syndr (MAS), included 57 reports, 1148 MAS pts (889 sJIA, 137 SLE). Most effective was high-dose GCs, IL-1 (83%) & IFNγ (93%) inhibitors, especially in sJIA-MAS. Also Ciclosporin, etoposide, Ruxolitinib https://t.co/4EnMOnlcYl https://t.co/PQnAZLvVwq
Dr. John Cush @RheumNow( View Tweet )
CARRA Consensus Treatment for Refractory Juvenile Dermatomyositis
CARRA has developed consensus treatment plans for the use of biologic disease-modifying antirheumatic drugs (bDMARDs) in patients with refractory, moderately severe juvenile dermatomyositis. Juvenile dermatomyositis is the most common form of idiopathic, inflammatory myositis in childhood, with
Read Article
NEW VIEWPOINT—Arthritis complicating inflammatory bowel disease—the future is now https://t.co/FyojGF6Pvx @DrLauraCoates #GITwitter https://t.co/kMewGTDQTc
Links:
The Lancet Rheumatology @TheLancetRheum( View Tweet )
Biologics Prevent AA amyloidosis progression to ESRD
MedPage Today
One of the most serious complications of rheumat0logic and autoimmune diseases can be prevented with biologic drugs, a single-center chart review suggested, and some such products may be more effective than others.
Among 83 patients receiving biologic agents for their underlying
Read Article
From LG cohort of myeloid neoplasms (861 MDS, 640 AML, 112 MDS/MPN, 89 MPN) autoimmune Rheum Dz (AIRD) found in 7.7% (lit suggests 8-30%), less in AML (4.7% vs 9.5% others). Common: RA (42%), CTD(18%), PMR (14%), vasculitis (12%), AxSpA (7%). https://t.co/ZXxOrZBunZ https://t.co/m5nIgrhohw
Dr. John Cush @RheumNow( View Tweet )
174 Active RA pts not responding to MTX were started on TCZ. High GM-CSF (> 5 ng/ml and > 10 ng/ml) at baseline were the independent predictors of poor response to TCZ at Wk24. high GM-CSF had signif higher DAS28-ESR & cytokine levels at baseline https://t.co/AreLBseJDq https://t.co/OyIOkiUOT1
Dr. John Cush @RheumNow( View Tweet )
Recent Blogs
